miR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma

Yamamoto,Kazuo; Seike,Masahiro; Takeuchi,Susumu; Soeno,Chie; Miyanaga,Akihiko; Noro,Rintaro; Minegishi,Yuji; Kubota,Kaoru; Gemma,Akihiko

doi:10.3892/or.2014.3481

miR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma

Authors:
- Kazuo Yamamoto
- Masahiro Seike
- Susumu Takeuchi
- Chie Soeno
- Akihiko Miyanaga
- Rintaro Noro
- Yuji Minegishi
- Kaoru Kubota
- Akihiko Gemma
View Affiliations

Affiliations: Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan
Published online on: September 16, 2014 https://doi.org/10.3892/or.2014.3481
Pages: 2365-2372

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pleural mesothelioma (MPM) is a rapidly fatal malignancy that is increasing in incidence in Japan. In this study, we performed gene and microRNA (miRNA) expression profiling to identify novel therapeutic targets in MPM cells. Based on relative sensitivities to pemetrexed (PEM) and the histone deacetylase (HDAC) inhibitor, vorinostat (SAHA), 211H cells were determined to be the only sensitive MPM cell line out of the 6 tested. On the same series of cell lines, we performed whole genome transcriptomic profiling via DNA microarrays and pathway analysis of the derived data. Of particular note, IL-18 gene expression levels were significantly higher in the cell lines that were either drug resistant or displayed intermediate sensitivity, compared to the sensitive 211H cell line. Pathway analysis revealed IL-18 as an important gene associated with drug sensitivity of MPM cells. A relationship between IL-18 overexpression and drug resistance was also observed following targeted assessment of 10 cytokine genes using quantitative RT-PCR. miRNA expression profiles were evaluated in the MPM cell line panel in order to discern the mechanism of IL-18 induction in the drug-resistant lines. We found that miR-379 and miR-411 belonged to the same cluster of miRNAs located on chromosome 14q32 that commonly target the IL-18 gene. Luciferase reporter assays revealed that miR-379 and miR-411 directly target the IL-18 gene. Introduction of miR-379 plus miR-411, as well as IL-18 silencing, significantly suppressed the invasive capacity of MESO1 cells in vitro. Furthermore, the use of either PEM or SAHA together with miR-379 plus miR-411 mimics mediated increased sensitivity to these drugs in MESO1 cells. These results suggest that the miR-379/411 cluster may provide new therapeutic opportunities for advanced MPM patients, depending on the nature of IL-18 gene expression.

View Figures

View References

1	Kaufman AJ and Pass HI: Current concepts in malignant pleural mesothelioma. Expert Rev Anticancer Ther. 8:293–303. 2008. View Article : Google Scholar : PubMed/NCBI
2	Hansen J, de Klerk NH, Musk AW and Hobbs MS: Environmental exposure to crocidolite and mesothelioma: exposure-response relationships. Am J Respir Crit Care Med. 157:69–75. 1998. View Article : Google Scholar : PubMed/NCBI
3	Robinson BWS and Lake RA: Advances in malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005. View Article : Google Scholar : PubMed/NCBI
4	Sugarbaker DJ, Flores RM, Jaklitsch MT, et al: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 117:54–63. 1999. View Article : Google Scholar
5	Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of PEM in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
6	Hurwitz JL, Stasik I, Kerr EM, et al: Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur J Cancer. 48:1096–1107. 2012. View Article : Google Scholar : PubMed/NCBI
7	Vandermeers F, Hubert P, Delvenne P, et al: Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res. 15:2818–2828. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ramalingam SS, Parise RA, Ramanathan RK, et al: Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 13:3605–3610. 2007. View Article : Google Scholar : PubMed/NCBI
9	Zitvogel L, Tesniere A and Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 6:715–727. 2006. View Article : Google Scholar : PubMed/NCBI
10	Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 5:263–274. 2005. View Article : Google Scholar : PubMed/NCBI
11	Seike M, Yanaihara N, Bowman ED, et al: Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst. 99:1257–1269. 2007. View Article : Google Scholar : PubMed/NCBI
12	Okamura H, Tsutsi H, Komatsu T, et al: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 378:88–91. 1995. View Article : Google Scholar : PubMed/NCBI
13	Coughlin CM, Salhany KE, Wysocka M, et al: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest. 101:1441–1452. 1998. View Article : Google Scholar : PubMed/NCBI
14	Son YI, Dallal RM, Mailliard RB, Egawa S, Jonak ZL and Lotze MT: Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res. 61:884–888. 2001.PubMed/NCBI
15	Park S, Cheon S and Cho D: The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol. 4:329–335. 2007.PubMed/NCBI
16	Johnson SM, Grosshans H, Shingara J, et al: Ras is regulated by the let-7 microRNA family. Cell. 120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
17	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
18	Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
19	Seike M, Goto A, Okano T, et al: MiR-21 is an EGFR-regulated anti-apoptonic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA. 106:12085–12090. 2009. View Article : Google Scholar : PubMed/NCBI
20	Pass HI, Goparaju C, Ivanov S, et al: hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 70:1916–1924. 2010. View Article : Google Scholar : PubMed/NCBI
21	Cioce M, Ganci F, Canu V, et al: Protumorigenic effects of miR-145 loss in malignant pleural mesothelioma. Oncogene. Nov 18–2013.(Epub ahead of print). View Article : Google Scholar
22	Shimokawa T, Seike M, Soeno C, et al: Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules. Br J Cancer. 106:867–875. 2012. View Article : Google Scholar : PubMed/NCBI
23	Gemma A, Li C, Sugiyama Y, et al: Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer. 6:1742006. View Article : Google Scholar : PubMed/NCBI
24	Kitamura K, Seike M, Okano T, et al: MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther. 13:444–453. 2014.PubMed/NCBI
25	Thodtmann R, Depenbrock H, Dumez H, et al: Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol. 17:3009–3016. 1999.PubMed/NCBI
26	Fakih MG, Pendyala L, Fetterly G, et al: A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res. 15:3189–3195. 2009. View Article : Google Scholar : PubMed/NCBI
27	Miyanaga A, Gemma A, Noro R, et al: Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther. 7:1923–1930. 2008. View Article : Google Scholar : PubMed/NCBI
28	Dinarello CA: The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 25:307–313. 2006. View Article : Google Scholar : PubMed/NCBI
29	Pollari S, Leivonen SK, Perälä M, Fey V, Käkönen SM and Kallioniemi O: Identification of microRNAs inhibiting TGF-β-induced IL-11 production in bone metastatic breast cancer cells. PLoS One. 7:e373612012.
30	Khan S, Brougham CL, Ryan J, et al: miR-379 regulates cyclin B1 expression and is decreased in breast cancer. PLoS One. 8:e687532013. View Article : Google Scholar : PubMed/NCBI
31	Yao L, Zhang Y, Chen K, et al: Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLoS One. 6:e246842011. View Article : Google Scholar : PubMed/NCBI
32	Terme M, Ullrich E, Aymeric L, et al: IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 71:5393–5399. 2011. View Article : Google Scholar : PubMed/NCBI